- Home
- AMRN vs INZY Comparison
AMRN vs INZY Comparison
Compare AMRN & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- INZY
- Stock Information
- Founded
- AMRN 1989
- INZY 2015
- Country
- AMRN Ireland
- INZY United States
- Employees
- AMRN N/A
- INZY N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- AMRN Health Care
- INZY Health Care
- Exchange
- AMRN Nasdaq
- INZY Nasdaq
- Market Cap
- AMRN 189.2M
- INZY 188.2M
- IPO Year
- AMRN 1993
- INZY 2020
- Fundamental
- Price
- AMRN $0.56
- INZY $1.36
- Analyst Decision
- AMRN Buy
- INZY Strong Buy
- Analyst Count
- AMRN 1
- INZY 8
- Target Price
- AMRN N/A
- INZY $17.75
- AVG Volume (30 Days)
- AMRN 1.7M
- INZY 784.0K
- Earning Date
- AMRN 02-27-2025
- INZY 03-11-2025
- Dividend Yield
- AMRN N/A
- INZY N/A
- EPS Growth
- AMRN N/A
- INZY N/A
- EPS
- AMRN N/A
- INZY N/A
- Revenue
- AMRN $241,021,000.00
- INZY N/A
- Revenue This Year
- AMRN N/A
- INZY N/A
- Revenue Next Year
- AMRN N/A
- INZY N/A
- P/E Ratio
- AMRN N/A
- INZY N/A
- Revenue Growth
- AMRN N/A
- INZY N/A
- 52 Week Low
- AMRN $0.43
- INZY $1.32
- 52 Week High
- AMRN $1.37
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- AMRN 60.59
- INZY 20.27
- Support Level
- AMRN $0.43
- INZY $1.32
- Resistance Level
- AMRN $0.49
- INZY $3.18
- Average True Range (ATR)
- AMRN 0.03
- INZY 0.27
- MACD
- AMRN 0.01
- INZY -0.15
- Stochastic Oscillator
- AMRN 91.43
- INZY 2.15
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.